C4 THERAPEUTICS, INC. Protein degraded. Disease targeted. Lives transformed.
May 2024
Forward-looking Statements and Intellectual Property
Forward-looking Statements
The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward- looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. These forward- looking statements include, but are not limited to, statements regarding the therapeutic potential of C4 Therapeutics, Inc.'s technology
and products. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among
the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, as well as the fact that the product candidates that we are developing or may develop may not demonstrate success in clinical trials. Prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The forward- looking statements included in this presentation are subject to a variety of risks and uncertainties, including those set forth in our most
recent and future filings with the Securities and Exchange Commission. Our actual results could vary significantly from those anticipated
in this presentation, and our financial condition and results of operations could be materially adversely affected. C4 Therapeutics, Inc. undertakes no obligation to update or revise the information contained in this presentation, whether as a result of new information, future events or circumstances or otherwise.
Intellectual Property
C4 Therapeutics, Inc. owns various registered and unregistered trademarks and service marks in the U.S. and internationally, including, without limitation, C4 THERAPEUTICS, our housemark logo, the name of our TORPEDO platform, and the names of our BIDAC and MONODAC degrader products. All trademarks, service marks, or trade names referred to in this presentation that we do not own are the property of their respective owners. Solely for convenience, the trademarks, service marks, and trade names in this presentation are referred to without the symbols ®, SM and , but those references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights to.
© 2024 C4 Therapeutics, Inc. | 2 |
C4T is a Recognized Leader in Delivering on the Promise of Targeted Protein Degradation
WORLD-CLASS DEGRADER PLATFORM
Our Mission
To deliver on the promise
of targeted protein
degradation science to create a new generation of medicines that transform patients' lives
Robust patent portfolio of novel cereblon binders; Demonstrated ability to design orally
bioavailable, catalytically efficient degraders
RIGOROUS TARGET SELECTION
Focus on targets with a clear degrader
rationale
BROAD DEGRADER APPROACH
MonoDAC and BiDAC degraders, as well as degrader-antibodyconjugates
CLINICAL PIPELINE
Oncology degraders against targets of high unmet need
© 2024 C4 Therapeutics, Inc. | 3 |
We Have Designed and Advanced Degraders into the Clinic Across a Range of Target Classes, Resulting in Robust Target Degradation
Interrogated Diverse | Attained |
Target Classes | IND Clearance |
Discovered degraders and advanced
4 INDs against a transcription factor, a chromatin modifier, and two kinases
1. Evaluated three programs in the clinic as of 1/9/2024 Investigational New Drug Application (IND)
Achieved Desirable | Degraded Target as |
Drug-like Properties | Predicted |
To date, we have evaluated
3 programs in the clinic1, with each demonstrating robust target degradation in patients
© 2024 C4 Therapeutics, Inc. | 4 |
Prioritized Pipeline to Deliver Near-Term Value
Program | Target | Indications | Discovery | Preclinical | Early phase | Late phase | Rights | |||
development | development | |||||||||
Cemsidomide | Multiple Myeloma & | |||||||||
IKZF1/3 | Non-Hodgkin's | |||||||||
(CFT7455) | ||||||||||
Lymphoma | ||||||||||
CFT1946 | BRAF | V600X Mutant | ||||||||
V600X | Cancers | |||||||||
CFT89191 | EGFR | Non-Small Cell Lung | ||||||||
L858R | Cancers | |||||||||
Undisclosed Discovery | Various Cancers | |||||||||
Stage Programs | ||||||||||
Autoimmune & | 2 targets | |||||||||
Cancer | ||||||||||
Undisclosed | Autoimmune & | 2 targets | ||||||||
Neurological | ||||||||||
Collaboration Programs | ||||||||||
Cancer | 1 target | |||||||||
Cancer | 2 targets | |||||||||
1. License and Collaboration Agreement with Betta Pharmaceuticals for development and commercialization in Greater China | ||||||||||
© 2024 C4 Therapeutics, Inc. | 5 |
2024 Milestones: Advancing High-potential Programs
Multiple Value Inflection Points over Next 12 Months with Sufficient Runway (into 20271) Beyond These Milestones
Cemsidomide
(CFT7455)
IKZF1/3
CFT1946
BRAF V600X
CFT8919
EGFR L858R
Discovery
- 2H 2024: Present updated data from Phase 1 dose escalation +dex trial in R/R MM
- 2H 2024: Present data from Phase 1 dose escalation monotherapy trial in R/R NHL
- By YE 2024: Complete Phase 1 dose exploration in R/R MM and R/R NHL
- 2Q 2024: Present preclinical data demonstrating differentiated activity in BRAF V600X melanoma, CRC, NSCLC, and brain metastasis models at AACR
- 2H 2024: Present data from Phase 1 dose escalation trial in melanoma, CRC, NSCLC, and other BRAF V600X cancers
- 2024: Support trial start-up activities related to Betta's Phase 1 dose escalation trial in China
- 1Q 2024: Collaboration with Merck KGaA, Darmstadt, Germany to discover two targeted protein degraders against critical oncogenic proteins
- 2024: Deliver development candidate to collaboration partner
1. Cash, cash equivalents and marketable securities as of March 31, 2024 were $299.2 million Dexamethasone (dex); Colorectal cancer (CRC); Non-small cell lung cancer (NSCLC); Year-end (YE)
© 2024 C4 Therapeutics, Inc. | 6 |
Cemsidomide (CFT7455)
Targeting IKZF1/3
Multiple Myeloma (MM)
- Non-Hodgkin'sLymphoma (NHL)
IKZF1/3 Degradation Drives Three Distinct Areas of Hematopoietic Biology; Degrading IKZF1/3 is a Validated Therapeutic Strategy in MM and NHL
IKZF1 / IKZF3
Transcription Factors
Drive MM and NHL Cell | Activate Fully | Regulate Hematopoietic |
Growth and Survival | Differentiated T-cells | Stem Cell Differentiation |
CD8+ | Hematopoietic | |
Stem Cell |
MM and
NHL Cells
Activated CD8+
Neutrophil
Consequences of IKZF1/3 Degradation:
• MM and NHL Cell Death | • T-cell Activation | • On-target Neutropenia |
Ikaros Family Zinc Finger proteins 1 and 3 (IKZF1/3); Multiple Myeloma (MM); Non-Hodgkin's Lymphoma (NHL)
© 2024 C4 Therapeutics, Inc | 8 |
Differentiated PK and Class-leading Catalytic Activity of Cemsidomide (CFT7455) Leads to Sustained Degradation Compared to Other Agents in this Class
Extended Plasma and Tumor Exposure
In Vivo Tumor PK
Leads to Optimized Degradation Kinetics
In Vivo Degradation Kinetics (48 hrs.)
Compound Concentration Plasma (ng/mL) or Tumor (ng/g)
100
10
1
0.1
CC92480 is not detectable after 4 hrs
CC92480 1000 | μg/kg plasma | |
CC92480 1000 | μg/kg tumor | |
CFT7455 | 100 | μg/kg plasma |
CFT7455 | 100 | μg/kg tumor |
CFT7455
DC80 (total)
Pomalidomide (3000 μg/kg) | |
Remaining/ TumorsH929-NCI | CC-92480 (1000 µg/kg) |
CFT7455 (100 μg/kg) | |
100 |
IKZF3of | 50 |
GAPDHin | |
Percent | to |
0
12 | 24 | 36 | 48 |
Hours |
Normalized | 0 | ||||
0 | 12 | 24 | 36 | 48 | |
Hours |
mezigdomide (CC-92480); Ikaros family zinc finger protein (IKZF3); multiple myeloma (MM); pharmacodynamics (PD); pharmacokinetics (PK); once daily (QD) Source: AACR 2022 presentation
© 2024 C4 Therapeutics, Inc | 9 |
Cemsidomide (CFT7455) Phase 1 Dose Escalation Trial's Goal is to Define the Safety Profile and Identify Signs of Anti-Tumor Activity in R/R MM and R/R NHL
Phase 1 Dose Escalation Trial
R/R MM
Monotherapy
Dosing: QD
21 days on/7 days off
N=5
Status: Complete
R/R MM | R/R MM | R/R NHL |
Monotherapy | Dex Combo | Monotherapy |
Dosing: MWF & QD | Dosing: MWF & QD | Dosing: MWF & QD |
14 days on/14 days | 14 days on/14 days | 14 days on/14 days |
off | off | off |
N=22 | N = ~20 | N = ~20 |
Status: Complete | Status: Ongoing | Status: Ongoing |
Endpoints
Primary:
- Safety and tolerability
- Determine the maximum tolerated doses
Secondary:
- Estimate anti-tumor activity
- Assess PK
Exploratory:
- Characterize target engagement
- Assess kinetics, depth, recovery and consistency of target engagement
- Assess immunomodulation
Pharmacokinetic (PK); Monday, Wednesday, Friday dosing (MWF); once daily (QD); Relapsed refractory multiple myeloma (R/R MM);
Relapsed refractory non-Hodgkin's lymphoma (R/R NHL); Dexamethasone (Dex)
© 2024 C4 Therapeutics, Inc | 10 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
C4 Therapeutics Inc. published this content on 08 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 May 2024 11:11:40 UTC.
